MannKind Corporation

NASDAQ:MNKD

Biotechnology

Healthcare
$4.07 -0.51%

-$0.02 today

Market cap
$1.31B
Beta
1.11
P/E (TTM)
-50.3
EPS (TTM)
-$0.08
52W Low $2.23High $6.51

Volume 2.12M

Average 5.73M

MNKD Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

MannKind CorporationNASDAQ: MNKD

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow turns negative

Q1 FY2026 financing cash flow was -$35.13M, compared with $1.39M a year earlier. Trailing-twelve-month financing cash flow was $278.74M. Over 3 fiscal years it compounded at +145.1% a year.

Context

  • Financing cash flow amounted to 90.3% of revenue in FY2025, up 42.2 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly financing cash flow holds near -$35.13M or moves back toward the trailing-twelve-month quarterly average of $69.68M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$35.13M-114.2% QoQ
Last fiscal yearDec 2025
$315.1M+329.6% YoY
LTMMar 2026
$278.74M+310.5% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2627.1%——
1 year+329.6%——
3-year CAGR+145.1%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
315.1M USD
Year-over-year change
+329.6%
4-year CAGR
+3.9%

Financing Cash Flow vs competitors

How MNKD compares with its peers on the latest reported figures

  • MNKD's LTM Mar 2026 financing cash flow of $278.74M is the largest of the 6 companies compared; the peer median is $5.69M.
  • Its year-over-year change of +310.5% is the 3rd highest of 6, against a peer median of +42.8%.
  • Financing cash flow amounts to 77.3% of revenue for MNKD, versus a peer median of 56.2%.
MNKD Competitors Peer median
Financing Cash Flow for MNKD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MNKDMannKind CorporationLTM Mar 2026$278.74M +310.5%+145.1%77.3%
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026$104.03M +42.8%-18.1%105.1%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$19.12M +27.6%-10.3%833.6%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$15.14M -54.2%——
TBPHTheravance Biopharma, Inc.LTM Mar 2026$7.97M +387.5%-83.8%7.3%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$5.69M +363.0%-55.3%1.8%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding MNKD) $5.69M+42.8%-36.7%56.2%

Competitors are the stored peer set for MNKD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(80.93M)(87.4M)(11.94M)27.59M5.86M
Depreciation & Amortization5.47M6.29M5.8M9.04M12.28M
Deferred Income Tax12.64M000(4.97M)
Stock-Based Compensation12.2M017.65M21.36M24.2M
Change in Working Capital(17.73M)(24.05M)14.63M(36.47M)(86.35M)
Accounts Receivables(776K)(11.81M)2.35M2.65M(4.76M)
Inventory(4.08M)(5.67M)4.57M(3.2M)10.4M
Accounts Payables1.37M4.1M(1.47M)(2.79M)(16.71M)
Other Working Capital(14.25M)(10.67M)9.18M(33.14M)(75.27M)
Other Non-Cash Items6.63M24.47M7.96M21M67.23M
Operating Cash Flow(61.71M)(80.7M)34.09M42.51M18.26M
Capital Expenditures(11.47M)(7.59M)(42.44M)(9.69M)(4.57M)
Acquisitions (Net)(56.06M)(15.34M)00(347.74M)
Purchases of Investments(199.13M)(5M)(79.1M)(273.79M)(157.8M)
Sales of Investments59.06M0119.17M58.13M221.72M
Other Investing Activities56.06M32.8M382K128.71M(16.41M)
Investing Cash Flow(151.54M)4.87M(1.99M)(96.65M)(304.8M)
Debt Repayment281.08M(1.09M)(6.86M)(133.17M)325M
Common Stock Issued1.89M22.56M6.89M(6.09M)1.99M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(12.7M)(62K)136.58M1.99M(11.89M)
Financing Cash Flow270.27M21.41M136.61M(137.27M)315.1M
Effect of Forex Changes00000
Net Change in Cash57.02M(54.42M)168.71M(191.4M)28.55M
Free Cash Flow(73.18M)(88.29M)(8.35M)32.82M13.69M

MannKind Corporation

NASDAQ:MNKD

Intrinsic Alpha fair value

Locked

Current Price

$4.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.